trending Market Intelligence /marketintelligence/en/news-insights/trending/ehFuJXGELN7XqReGH-p-2A2 content esgSubNav
In This List

FDA Watch: Approval for Bristol-Myers Squibb; designation for CRISPR, Vertex

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation

Blog

Using Credit Analytics to Avoid Mispricing Insurance Premiums

Blog

Post-Webinar Q&A: Integrating Climate Risks into Credit Risk Portfolios


FDA Watch: Approval for Bristol-Myers Squibb; designation for CRISPR, Vertex

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Jan. 4.

Approvals

* Bristol-Myers Squibb Co.'s Sprycel, in combination with chemotherapy, for children ages one and up with Philadelphia chromosome-positive acute lymphoblastic leukemia. Sprycel is already approved to treat certain patients with similar subtypes of acute lymphoblastic leukemia.

SNL Image
FDA headquarters in Silver Spring, Md.
Source: Associated Press

Priority review

* Heron Therapeutics Inc.'s HTX-011, a non-opioid medication for pain. The application's target action date is April 30. The FDA previously granted HTX-011 breakthrough-therapy status.

Fast track

* CRISPR Therapeutics AG and Vertex Pharmaceuticals Inc.'s CTX001, for sickle cell disease. The FDA lifted a clinical hold on CTX001 in October 2018.

* ProQR Therapeutics NV's QR-421a, for vision loss associated with Usher syndrome type 2 and nonsyndromic retinitis pigmentosa caused by mutations in certain genes.